HomeCompareETHZW vs ABBV

ETHZW vs ABBV: Dividend Comparison 2026

ETHZW yields 22222.22% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETHZW wins by $149416168260246929408.00M in total portfolio value
10 years
ETHZW
ETHZW
● Live price
22222.22%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$149416168260246929408.00M
Annual income
$148,105,114,959,632,270,000,000,000.00
Full ETHZW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ETHZW vs ABBV

📍 ETHZW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETHZWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETHZW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETHZW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETHZW
Annual income on $10K today (after 15% tax)
$1,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$125,889,347,715,687,420,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ETHZW beats the other by $125,889,347,715,687,420,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETHZW + ABBV for your $10,000?

ETHZW: 50%ABBV: 50%
100% ABBV50/50100% ETHZW
Portfolio after 10yr
$74708084130123464704.00M
Annual income
$74,052,557,479,816,130,000,000,000.00/yr
Blended yield
99.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ETHZW
No analyst data
Altman Z
-22.0
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETHZW buys
0
ABBV buys
0
No recent congressional trades found for ETHZW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETHZWABBV
Forward yield22222.22%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$149416168260246929408.00M$102.3K
Annual income after 10y$148,105,114,959,632,270,000,000,000.00$24,771.77
Total dividends collected$149329735952949411840.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ETHZW vs ABBV ($10,000, DRIP)

YearETHZW PortfolioETHZW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,232,922$2,222,222.22$11,550$430.00+$2.22METHZW
2$466,132,160$463,742,932.96$13,472$627.96+$466.12METHZW
3$90,973,846,036$90,475,084,624.93$15,906$926.08+$90973.83METHZW
4$16,599,954,764,518$16,502,612,749,259.23$19,071$1,382.55+$16599954.75METHZW
5$2,831,989,953,832,695$2,814,228,002,234,661.00$23,302$2,095.81+$2831989953.81METHZW
6$451,734,606,477,112,800$448,704,377,226,511,900.00$29,150$3,237.93+$451734606477.08METHZW
7$67,374,432,085,560,830,000$66,891,076,056,630,320,000.00$37,536$5,121.41+$67374432085560.79METHZW
8$9,395,959,573,643,529,000,000$9,323,868,931,311,981,000,000.00$50,079$8,338.38+$9395959573643530.00METHZW
9$1,225,283,458,518,369,500,000,000$1,215,229,781,774,571,000,000,000.00$69,753$14,065.80+$1225283458518369536.00METHZW
10$149,416,168,260,246,920,000,000,000$148,105,114,959,632,270,000,000,000.00$102,337$24,771.77+$149416168260246929408.00METHZW

ETHZW vs ABBV: Complete Analysis 2026

ETHZWStock

ETHZilla operates in digital asset management, gaming, and entertainment. The Company is developing an Ether (ETH) accumulation vehicle to serve as a benchmark for on-chain treasury management among public companies, supported by Electric Capital and a DeFi Council of industry experts. Its strategy targets yield generation beyond traditional ETH staking while advancing gaming initiatives and pursuing monetization of legacy biotechnology assets from its origins as a biotech company.

Full ETHZW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ETHZW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETHZW vs SCHDETHZW vs JEPIETHZW vs OETHZW vs KOETHZW vs MAINETHZW vs JNJETHZW vs MRKETHZW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.